Dublin, 31 Dec. 2021 (GLOBE NEWSWIRE) — The “Chinese Nifedipine Market Investigation Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.
According to the analyst’s market research, the sales value of nifedipine in the Chinese market increased year on year from 2016 to 2019. In 2020, due to the impact of Covid-19 on the whole of medical diagnosis and treatment services, the sales value of nifedipine in the Chinese market fell to CNY 730 million, and the CAGR of nifedipine from 2016 to 2020 was 4.42%.
The analyst expects that with the relief of Covid-19, the sales value of Nifedipine in the Chinese market will experience restorative growth from 2021 to 2025. Moreover, in recent years, nearly 20 million people around the world died from cardiovascular and cerebrovascular diseases caused by hypertension and coronary heart disease every year.
Nifedipine is a dihydropyridine calcium channel blocker, which is primarily used to bind to L-type calcium channels. Nifedipine is primarily used to treat chronic stable angina pectoris, angina pectoris vasospasm (angina pectoris, variant of angina pectoris) and essential hypertension. Nifedipine was developed by Bayer AG, and Bayer AG’s nifedipine is marketed as ADALAT. By 2020, there are several manufacturers in the Chinese nifedipine market, among which Bayer AG holds the highest market share by sales value.
An estimated 300 million patients live with high blood pressure in China. As China’s aging population is becoming more and more severe, the number and prevalence of patients are increasing year by year. Therefore, there is an upward trend in the sales volume of nifedipine for the treatment of angina pectoris and hypertension.
At the same time, compared to similar drugs, nifedipine has a longer action time, fewer doses, more stable blood levels and fewer toxic and side effects. Based on these advantages, the sales volume and sales value of nifedipine in the Chinese market will continue to grow from 2021 to 2025.
- The impact of COVID-19 on the Chinese nifedipine market
- China nifedipine sales value 2016-2020
- Competitive landscape of Chinese nifedipine market
- nifedipine price in china
- Nifedipine Price in China by Regions and Manufacturers
- Analysis of factors affecting the development of the Chinese nifedipine market
- China nifedipine market outlook from 2021 to 2025
Main topics covered:
1 Relevant concepts of nifedipine
1.1 Indications for nifedipine
1.2 Nifedipine Development in China
1.3 Government approval of nifedipine in China
1.4 The impact of COVID-19 on nifedipine sales in China
2 China Nifedipine Sales, 2016-2020
2.1 Nifedipine Sales Value
2.1.1 Overall sales value
2.1.2 Sales Value by Region
2.2 Nifedipine Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 China Nifedipine Sales by Dosage Form, 2016- 2020
2.3.1 Controlled release tablets
2.3.3 Sustained-release tablets
2.3.4 Soft capsules
3 Analysis of Nifedipine Key Manufacturers in China, 2016-2020
3.1 Nifedipine Key Manufacturers Market Share Analysis
3.1.1 Market Share Survey by Sales Value
3.1.2 Market Share Survey by Sales Volume
3.2 Bayer AG
3.2.1 Company Profile
3.2.2 China ADALAT (Nifedipine by Bayer AG) Sales
3.3 Shanghai Shyndec Pharmaceutical Co., Ltd.
3.3.1 Company Profile
3.3.2 China Xinran (Nifedipine by Shanghai Shyndec Pharmaceutical Co., Ltd.) Sales
3.4 Qingdao Huanghai Pharmaceutical Co., Ltd.
3.4.1 Company Profile
3.4.2 China Maikaofen (Nifedipine by Qingdao Huanghai Pharmaceutical Co., Ltd.) Sales
3.5 Beijing Honglin Pharmaceutical Co., Ltd.
3.5.1 Business Profile
3.5.2 China Nifuda (Beijing Honglin Pharmaceutical Co., Ltd. Nifedipine) Sales
3.6 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.
3.6.1 Company Profile
3.6.2 China Shansu (Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.’s Nifedipine) Sales
4 Nifedipine Price for Different Manufacturers in China, 2020-2021
4.1 Bayer AG (ADALAT)
4.2 Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)
4.3 Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)
4.4 Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)
4.5 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd. (Shansu)
5 China Nifedipine Market Outlook, 2021- 2025
5.1 Influencing Factors of China Nifedipine Market Development
5.1.1 The impact of COVID-19 on the Chinese nifedipine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast
- Bayer SA (ADALAT)
- Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)
- Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)
- Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)
- Nanjing Hailing Pharmaceutical Co., Ltd. Yangtze River Pharmaceutical Group (Shansu)
For more information on this report, visit https://www.researchandmarkets.com/r/ephsng